| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: present invention refers to molecular biology, and can be used in neurology and endocrinology. A ligand-binding domain of a soluble corticotrophin release factor receptor type 2 (sCRFR2) which is characterised by an ability to inhibit said receptor activity in the presence of a ligand selected from a group including the corticotrophin release factor, urocortin-1, urocortin-2, urocortin-3 and stresscophin is produced. What is offered is using the produced sCRFR2 or its conjugate with polyethylene glycol as a CRFR2 activity modulator and/or a pharmacological effect of a bound ligand. ^ EFFECT: production of the new compositions. ^ 6 cl, 17 dwg, 2 tbl, 1 ex |
